Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Aptevo Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH
Ticker
Exchange
SIC #
Website
Latest Ticker
APVO
Nasdaq
8731
http://aptevotherapeutics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Aptevo Therapeutics Inc
Aptevo Therapeutics Announces Closing of $4.6 Million Public Offering
- Apr 15th, 2024 8:05 pm
Aptevo Therapeutics Announces Pricing of $4.6 Million Public Offering
- Apr 11th, 2024 12:00 pm
Aptevo Therapeutics Provides Pipeline Update
- Apr 10th, 2024 1:00 pm
Aptevo Participating in The Springtime Partnering Event, a Bio-Europe Conference
- Mar 18th, 2024 10:00 am
Alligator Bioscience and Aptevo Therapeutics Announce Positive Interim Data of Dose Escalation Phase of ALG.APV-527 Phase 1 Study in Solid Tumor Cancers Expressing Tumor Antigen 5T4
- Mar 7th, 2024 12:55 pm
Aptevo Therapeutics Reports 2023 Financial Results and Provides a Business Update
- Mar 5th, 2024 1:05 pm
Aptevo Therapeutics Announces 1-for 44 Reverse Stock Split As Part of Nasdaq Compliance Plan
- Mar 4th, 2024 2:00 pm
Aptevo Therapeutics Reports 3Q23 Financial Results and Provides a Business Update
- Nov 14th, 2023 1:05 pm
Aptevo to Present at Bio-Europe Conference
- Nov 1st, 2023 11:45 am
Aptevo Therapeutics Reports 2Q23 Financial Results and Provides a Business Update
- Aug 10th, 2023 12:05 pm
10 Oversold Value Stocks To Buy
- Aug 6th, 2023 11:14 am
Aptevo Therapeutics Inc. Announces Closing of Previously Announced $5 Million Public Offering
- Aug 4th, 2023 10:40 pm
Aptevo Therapeutics Inc. Announces Pricing of $5 Million Public Offering
- Aug 2nd, 2023 2:15 am
7 Millionaire-Maker Penny Stocks to Buy Before the Window Closes
- Jul 30th, 2023 6:17 pm
Aptevo Announces Positive Duration of Remission Data from Phase 1b Expansion Trial Evaluating the Bispecific APVO436 for AML
- Jul 18th, 2023 12:05 pm
Aptevo Therapeutics Reports 1Q23 Financial Results and Provides Business Update
- May 11th, 2023 12:05 pm
Scroll